Detalles de la búsqueda
1.
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
Depress Anxiety;
38(11): 1120-1130, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34293233
2.
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
CNS Spectr;
21(6): 466-477, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27629292
3.
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis.
J Clin Psychiatry;
84(6)2023 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37756123
4.
Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis.
J Pharmacokinet Pharmacodyn;
39(2): 161-76, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22270322
5.
Telehealth-Based Psychoeducation for Caregivers: The Family Intervention in Recent-Onset Schizophrenia Treatment Study.
JMIR Ment Health;
9(4): e32492, 2022 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35436231
6.
Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey.
Neuropsychiatr Dis Treat;
18: 1479-1493, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35910684
7.
Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey.
Neuropsychiatr Dis Treat;
18: 2003-2019, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36101838
8.
Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections.
Neuropsychiatr Dis Treat;
18: 1927-1937, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36065384
9.
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
J Clin Psychiatry;
83(6)2022 09 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-36149841
10.
Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study.
J Clin Psychopharmacol;
31(1): 108-14, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21192153
11.
Direct and Indirect Costs Among Caregivers of Patients With Major Depressive Disorder and Suicidal Ideation or Suicidal Attempt.
Prim Care Companion CNS Disord;
23(4)2021 Aug 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34384005
12.
Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study.
Psychiatry Res;
293: 113376, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32818917
13.
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
J Clin Psychopharmacol;
29(3): 239-47, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19440077
14.
Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.
Early Interv Psychiatry;
12(1): 55-65, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26403322
15.
Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study.
PLoS One;
13(2): e0193453, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29489906
16.
Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission.
J Clin Psychiatry;
78(1): 105-114, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27487193
17.
Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
J Natl Med Assoc;
97(10 Suppl): 11S-16S, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16350601
18.
Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
Adv Ther;
22(5): 498-512, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16418159
19.
Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
J Med Econ;
18(8): 637-45, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25851616
20.
Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
J Clin Psychiatry;
76(5): 554-61, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25938474